Current evidence and emerging drug therapies for overactive bladder

Area of Science:

• Urology
• Pharmacology

Background:

• Overactive bladder (OAB) significantly impacts quality of life and healthcare resources.
• Antimuscarinic agents are traditional OAB treatments but suffer from poor compliance due to side effects and limited efficacy.
• The need for improved OAB therapies drives research into novel pharmacological and procedural interventions.

Purpose of the Study:

• To review current and emerging therapeutic options for overactive bladder.
• To discuss the evidence base for novel OAB treatments.
• To highlight ongoing research in OAB drug development and combination therapies.

Main Methods:

• Literature review of established and novel overactive bladder treatments.
• Analysis of clinical evidence for antimuscarinics, mirabegron, and botulinum toxin.
• Exploration of current research trends in OAB pharmacotherapy.

Main Results:

• Antimuscarinics remain a first-line option despite compliance issues.
• Mirabegron (a B3-adrenoreceptor agonist) is an effective alternative therapy.
• Intravesical botulinum toxin is a valuable option for refractory overactive bladder cases.

Conclusions:

• Despite advancements, many patients experience treatment ineffectiveness or adverse events.
• Ongoing research focuses on new drugs and combination therapies to address unmet needs in OAB management.
• A comprehensive understanding of OAB pathophysiology is crucial for developing next-generation treatments.